CytomX Therapeutics, Inc. (Nasdaq: CTMX) has appointed Charles Fuchs, M.D., M.P.H., to its board of directors, the clinical-stage biopharmaceutical company announced July 27, 2026.

Fuchs most recently served as chief medical officer of Tubulis, where he oversaw clinical strategy and pipeline development. Before that, he was senior vice president and global head of oncology and hematology drug development at Genentech and Roche, where he led multiple therapies to regulatory approval, including Lunsumio, Columvi, Polivy, and Tecentriq.

Prior to his industry roles, Fuchs served as director of the Yale Cancer Center and physician in chief at Smilow Cancer Hospital. He also held senior positions at Dana-Farber Cancer Institute, including chief of the gastrointestinal cancer division, and at Harvard Medical School. He founded EvolveImmune Therapeutics and currently serves as a senior advisor to Frazier Life Sciences. He holds an M.D. from Harvard Medical School and an M.P.H. from the Harvard T.H. Chan School of Public Health.

"Dr. Fuchs is a highly accomplished oncology expert and industry leader with more than three decades of experience across academia and global drug development," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.

Fuchs commented on the appointment, saying he is "particularly excited to see the potential of the Varseta-M EpCAM ADC program to make an important impact for colorectal cancer patients."

CytomX's clinical-stage pipeline includes varsetatug masetecan, known as Varseta-M, a masked antibody-drug conjugate targeting EpCAM initially being developed for metastatic colorectal cancer, and CX-801, a masked interferon alpha-2b cytokine being developed for metastatic melanoma.